Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1270-1276 , December 2006

Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma

  • Marco Ladetto

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • Corresponding Author InformationCorrespondence and reprint requests: Marco Ladetto, MD, Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy.
    • ,
  • Michele Magni

      Affiliations

    • Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Gloria Pagliano

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Federica De Marco

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Daniela Drandi

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Irene Ricca

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Monica Astolfi

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Paola Matteucci

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Anna Guidetti

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Barbara Mantoan

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Chiara Lobetti Bodoni

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Manuela Zanni

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Mario Boccadoro

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy
    • ,
  • Alessandro M. Gianni

      Affiliations

    • Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    • Department of Medical Oncology, University of Milan, Milan, Italy
    • ,
  • Corrado Tarella

      Affiliations

    • Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Torino, Italy

Received 5 April 2006 ,Accepted 17 July 2006.

References 

  1. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol. 2004;83:71–77
  2. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90:4212–4221
  3. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16:13–18
  4. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin’s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89:724–731
  5. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol. 2005;16:618–624
  6. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol. 2005;23:6409–6414
  7. Brugger W. Clearing minimal residual disease with rituximab consolidation therapy. Semin Oncol. 2004;31(suppl 2):33–37
  8. Foran JM, Rohatiner Ama ZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317–324
  9. Ghielmini M, Schmitz SF, Burki K, et al. Swiss Group for Clinical Cancer Research (SAKK) The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann Oncol. 2000;11(suppl 1):123–126
  10. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984–1992
  11. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864–869
  12. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749–755
  13. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107:2271–2278
  14. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244–1253
  15. Olsson K, Gerard CJ, Zehnder J, et al. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Leukemia. 1999;13:1833–1842
  16. Ladetto M, Donovan JW, Harig S, et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant. 2000;6:241–253
  17. Donovan JW, Ladetto M, Zou G, et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 2000;95:2651–2658
  18. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11:1793–1798
  19. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood. 1993;81:3449–3457
  20. Corradini P, Ladetto M, Astolfi M, et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol. 1996;94:376–378
  21. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088–1095
  22. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106:349
  23. Van Oers MHJ, Van Glabbeke M, Teodorovic I, et al. Chimeric Anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed /resistant Follicular Non-Hodgkin’s lymphoma: final analysis of a phase III randomized intergroup clinical trial. Blood. 2005;106:353
  24. Ghielmini M, Schmitz SFH, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705–711
  25. Paschka P, Merx K, Hochhaus A. Molecular surveillance of chronic myeloid leukemia patients in the imatinib era—evaluation of response and resistance. Acta Haematol. 2004;112:85–92
  26. Lo Coco F, Breccia M, Noguera N, Miller WH. Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. Best Pract Res Clin Haematol. 2003;16:653–670

PII: S1083-8791(06)00493-9

doi: 10.1016/j.bbmt.2006.07.007

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1270-1276 , December 2006

Article Tools

* Image Usage & Resolution